AAM
PTCT icon

Advisors Asset Management’s PTC Therapeutics PTCT Stock Holding History

Advisors Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
15,280
+6,234
+69% +$450K 0.02% 754
2026
Q1 		$616K Buy
9,046
+1,586
+21% +$112K 0.01% 918
2025
Q4 		$567K Buy
+7,460
New +$542K 0.01% 916
2022
Q4 		– Sell
-5,822
Closed -$292K – 1507
2022
Q3 		$292K Sell
5,822
-341
-6% -$16.7K 0.01% 1065
2022
Q2 		$247K Buy
+6,163
New +$216K ﹤0.01% 1115
2022
Q1 		– Sell
-10,585
Closed -$422K – 1017
2021
Q4 		$422K Sell
10,585
-285
-3% -$10.9K 0.01% 1052
2021
Q3 		$404K Buy
10,870
+10
+0.1% +$411 0.01% 1075
2021
Q2 		$459K Buy
10,860
+156
+1% +$6.68K 0.01% 1031
2021
Q1 		$507K Buy
10,704
+2,298
+27% +$136K 0.01% 1012
2020
Q4 		$513K Buy
8,406
+5,017
+148% +$296K 0.01% 959
2020
Q3 		$158K Buy
3,389
+1,570
+86% +$77.3K ﹤0.01% 1231
2020
Q2 		$92K Buy
+1,819
New +$89.4K ﹤0.01% 1318

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Advisors Asset Management's PTCT Position: Q2 2026 in Review

Advisors Asset Management increased its PTC Therapeutics (PTCT) stake by 69% in Q2 2026, buying an estimated $450K and bringing the position to 15,280 shares worth $1.25M. The position accounts for 0.02% of the portfolio, ranked #754.

Advisors Asset Management first reported a position in PTCT in Q2 2020 and has held it in 12 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Advisors Asset Management held 15,280 shares of PTC Therapeutics worth $1.25M as of Q2 2026.
  • Advisors Asset Management bought 6,234 PTC Therapeutics shares in Q2 2026, an estimated $450K.
  • PTC Therapeutics made up 0.02% of Advisors Asset Management's portfolio in Q2 2026, its #754 holding.
  • Advisors Asset Management first reported a position in PTC Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.